NCT Number: NCT03972657
Phase: Phase 1|Phase 2
Trial Summary: The primary objectives of the study in Dose Escalation are to evaluate safety, tolerability, and pharmacokinetics (PK) of REGN5678 alone and in combination with cemiplimab and in D – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Regeneron Pharmaceuticals
Acronym:
Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer and Other Tumors
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives